Moomoo AIのまとめ
A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.
A group of entities and individuals, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, have filed an amended Schedule 13G/A with the SEC, indicating they no longer beneficially own more than five percent of Avalo Therapeutics, Inc.'s common stock as of December 31, 2023. The filing, dated February 14, 2024, confirms that each reporting person within the group holds zero shares and has zero percent ownership of the class, signifying a complete divestment from Avalo Therapeutics. The entities and individuals are primarily organized under the laws of Delaware, with Shah and Koh being United States citizens. The filing ensures that the disposition of the shares is not for the purpose of changing or influencing the control of Avalo Therapeutics.
Venrock Healthcare Capital Partners III、VHCP Co-Investment Holdings III、Venrock Healthcare Capital Partners EG、VHCP Management III、VHCP Management EG、Nimish Shah、およびBong Kohを含む一群の団体および個人がSECに修正されたスケジュール13G/Aを提出し、2023年12月31日現在Avalo Therapeutics, Inc.の普通株式を5％以上保有していないことを示しています。この2024年2月14日付けの提出により、グルー...すべて展開
Venrock Healthcare Capital Partners III、VHCP Co-Investment Holdings III、Venrock Healthcare Capital Partners EG、VHCP Management III、VHCP Management EG、Nimish Shah、およびBong Kohを含む一群の団体および個人がSECに修正されたスケジュール13G/Aを提出し、2023年12月31日現在Avalo Therapeutics, Inc.の普通株式を5％以上保有していないことを示しています。この2024年2月14日付けの提出により、グループ内の各報告者が0株式を保有し、クラスの所有権0％を持っていることが確認されており、Avalo Therapeuticsからの完全な離脱を示しています。これらの団体および個人は主にデラウェア州法に基づいて組織されており、ShahとKohはアメリカ合衆国市民です。提出は、株式の処分がAvalo Therapeuticsの支配の変更または影響を目的としていないことを確認しています。
役に立った
役に立たない